Cell-Easy
PrivateLast Round
Grant
Apr 14, 2026
Total Funding Raised
$18.31M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Cell-Easy operates in Healthcare & Life Sciences and is based in Toulouse. Its latest recorded funding round was a Grant round in February 2022.
Cell-Easy is a biotechnology company that operates as a Contract Development and Manufacturing Organization (CDMO) specializing in cell therapy, providing services from process development to GMP production for biotech and pharma companies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Biotech Equipment, Compliance, Quality Management
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cell-Easy Comparables
Compare Cell-Easy with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stemmatters | 86% | |
| Cellex Cell Professionals GmbH | 82% | |
| Cellistic | 82% |
For institutional investors. Book with your work email.
Cell-Easy Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 14, 2026 | ||||
| Grant | Feb 28, 2022 | ||||
| Series A | Dec 8, 2020 | ||||
| Angel | Dec 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cell-Easy Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Région Occitanie | Grant |
| M Capital | Series A |
| IRDI Soridec Gestion | Series A |
| Bpifrance | Grant |
| Mérieux Equity Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Open roles increased to 12, 34% of headcount.
- Jul 27, 2026
Grew 16% QoQ, from 32 to 37 employees.
For institutional investors. Book with your work email.
Cell-Easy Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cell-Easy's valuation, stock price, and market status.
Is Cell-Easy a public or private company?
Cell-Easy is a private company.
What is the current stock price of Cell-Easy?
Cell-Easy is a private company, so its shares have no public market price. Caplight tracks Cell-Easy's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cell-Easy worth (valuation)?
Valuation information for Cell-Easy is not publicly available.
Can I buy Cell-Easy stock?
Cell-Easy shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cell-Easy's last funding round?
Cell-Easy's most recent funding round was Grant on April 14, 2026.
Who are the main investors in Cell-Easy?
Key investors in Cell-Easy include Mérieux Equity Partners.
Will Cell-Easy IPO soon?
No public IPO plans have been announced for Cell-Easy.
How can I track Cell-Easy secondary market activity?
Caplight tracks bids, offers, and trades in Cell-Easy's shares on secondary markets.